Long-Term Survivors of Multiple Myeloma Have Persistent Immune Alterations
Using an advanced multi-omics approach, researchers in Germany discovered that long-term survivors of multiple myeloma (MM) have both reversible and irreversible disease- ...
Mass Spectrometry an Effective Method to Detect Measurable Residual Disease in Multiple Myeloma
Quantitative immunoprecipitation mass spectrometry (QIP-MS) can detect measurable residual disease (MRD) in the peripheral blood of patients whose multiple myeloma ...
EMD Lesions Comprise Multicellular Ecosystems With New Therapeutic Avenues
Extramedullary disease (EMD), a difficult-to-treat, high-risk feature of multiple myeloma (MM), comprises T-cell exhaustion and profound genomic heterogeneity ...
MRD Status Important Prognostic Factor for R/R MM Treated With T-Cell Redirecting Therapies
Measurable residual disease (MRD)-negative complete response (CR) was the most relevant prognostic factor identified among patients with relapsed or refractory multiple myeloma ...
Therapy-Related Acute Leukemia Following AHCT for MM Remains Uncommon, Outcomes Remain Poor in Retrospective Analysis
Among patients who develop therapy-related acute leukemia after autologous hematopoietic cell transplantation (AHCT) for multiple myeloma (MM), long-term survival ...
Isatuximab Can Be Given as a Shorter Intravenous Infusion to Patients With Multiple Myeloma, New Trial Shows
A new clinical trial has found that a 30-minute intravenous (IV) infusion of isatuximab for patients with newly diagnosed multiple myeloma (NDMM) is safe and feasible ...
Daratumumab Shows Better Outcomes Than Active Monitoring for SMM
Clinicians currently treat patients with high-risk smoldering multiple myeloma (SMM) by actively monitoring them. However, new results indicate that these patients not only tolerate ...
BCMA/CD19 Dual-Targeting CAR T-Cell Therapy Shows Promising Efficacy in R/R MM
A B-cell maturation antigen (BCMA)/CD19 dual-targeting chimeric antigen receptor (CAR) T-cell therapy product — called KQ-2003 —showed early signs of efficacy in a small study ...
Daratumumab Plus Lenalidomide Combination Improves Conversion to MRD-Negative Status in Post-Transplant Patients With MM
The combination of daratumumab plus lenalidomide (D-R) resulted in more patients with newly diagnosed multiple myeloma (NDMM) converting from measurable residual disease ...
Daratumumab Plus Lenalidomide Shows MRD, PFS Benefit in Newly Diagnosed MM After AHCT in Clinically Relevant Subgroups
In anti-CD38-naïve patients with newly diagnosed multiple myeloma (NDMM) and measurable residual disease (MRD) after front-line autologous hematopoietic cell transplant ...
